We showed that TP53 alterations are also particularly enriched in class 2 and, particularly, class 3 BRAF-altered NSCLC patients compared to those with class 1 alterations, which may help in explaining the more aggressive behavior of these tumors and the poor outcomes reported in literature [27,67,68,69]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.